ReNeuron Group (RNUGF) Stock Price, News & Analysis

Company Overview

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

Key Stats

• Today's Range: $0.0011 to $0.0011
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.05
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $60,000.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RNUGF Stock Analysis - Frequently Asked Questions

How have RNUGF shares performed this year?

ReNeuron Group's stock was trading at $0.0011 at the beginning of the year. Since then, RNUGF shares have increased by 0.0% and is now trading at $0.0011.
View the best growth stocks for 2025 here.

How do I buy shares of ReNeuron Group?

Shares of RNUGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 1/21/2025
• Fiscal Year End: 3/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Private households
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:RNUGF
• Previous Symbol: NASDAQ:RNUGF
• CUSIP: N/A
• CIK: N/A
• Web: www.reneuron.com
• Phone: 44-20-3819-8400
• Fax: N/A
• Employees: 26
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $640,000.00
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.11 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: $60,000.00
• Optionable: Not Optionable
• Beta: 0.03